Fourth, as this study included patients enrolled between November 2011 and December 2015, advancements in HF management—such as the introduction of angiotensin receptor–neprilysin inhibitors (ARNIs) and sodium–glucose co-transporter 2 (SGLT-2) inhibitors [34]—are not reflected in our findings. This evidence concerns the gene SLC5A2 and hydrops fetalis.